AZD2516

AZD2516 is an orally administered small molecule drug developed by AstraZeneca. It acts as a selective antagonist of the metabotropic glutamate receptor 5 (mGluR5), a receptor implicated in the modulation of synaptic transmission and neuronal excitability. The drug was investigated primarily for the treatment of chronic neuropathic pain and gastro-oesophageal reflux disease (GERD). Clinical development included studies assessing its safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy volunteers and patients with relevant conditions. Despite initial promise as an analgesic targeting nervous system diseases via mGluR5 antagonism, clinical trials were discontinued after phase I/II due to unspecified reasons[3][4][7][8].